Sinopharm-led consortium offers to take HK-listed China-TCM private in $3b deal

FILE PHOTO: The logo of Sinopharm, China's National Pharmaceutical Group Corporation is pictured in Beijing, China January 18, 2022. REUTERS/Fabrizio Bensch/File Photo

Rishav Chatterjee

21 February, 2024

China TCM Sinopharm

Printed by Unregistered user on Fri, 05 Dec 2025 18:17:35 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

Sinopharm-led consortium offers to take HK-listed China-TCM private in $3b deal

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

You may also like

Sinopharm decides not to take China Traditional Chinese Medicine private

Boyu, Sinopharm among shortlisted bidders for drugmaker Mundipharma's China unit

Read more from Greater China

HongShan aims for $2.9b sale of Golden Goose to Permira by Christmas: report

Baidu’s Kunlunxin eyes Hong Kong IPO after $283m fundraising

Sinopharm-led consortium offers to take HK-listed China-TCM private in $3b deal

Register Now to Unlock Premium Content

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

You may also like

Sinopharm decides not to take China Traditional Chinese Medicine private

Boyu, Sinopharm among shortlisted bidders for drugmaker Mundipharma's China unit

Read more from Greater China

HongShan aims for $2.9b sale of Golden Goose to Permira by Christmas: report

Baidu’s Kunlunxin eyes Hong Kong IPO after $283m fundraising